Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Abcam Introduces Exclusive Range of Highly Validated Antibody Conjugates

Published: Wednesday, September 03, 2014
Last Updated: Wednesday, September 03, 2014
Bookmark and Share
Offering reliable and specific research tools for multi-color experiments.

Abcam plc has announced that it has launched an exclusive range of highly validated conjugated antibodies for use in key imaging applications including immunofluorescence, flow cytometry, and fluorescent western blotting.

Abcam’s conjugated antibodies enable scientists to easily perform multi-protein analysis. It is essential for scientists to study and image proteins in their multi-component state rather than individually, as research findings indicate that proteins rarely operate in isolation but function within multi-protein complexes.

The majority of the new antibodies are developed using Abcam’s RabMAb® technology, and are conjugated to Alexa Fluor® dyes, HRP, or biotin, combining high signal to noise ratios with high specificity. Each antibody has been produced and extensively validated by Abcam’s scientists. Performance data including images, references and customer reviews is provided with each product.

Matthew Roe, Head of Reagents, Abcam, commented: “Product quality is of critical importance to Abcam. We’re developing our in-house product ranges, focusing on high production standards and verifying quality though additional in-house and independent validation.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abcam Acquires AxioMx
AxioMx provides a unique, cost-effective, and proprietary platform to produce recombinant monoclonal antibodies complementing Abcam's existing innovative production capabilities.
Friday, November 13, 2015
Abcam Acquires Firefly BioWorks
Acquisition will expand Abcam’s capabilities in multiplex analysis.
Wednesday, January 21, 2015
Abcam Partners with A*STAR’s Institute of Molecular and Cell Biology
Abcam Partners with A*STAR’s Institute of Molecular and Cell Biology.
Thursday, January 08, 2015
Abcam plc Announces Board Appointment
Appointment of Sue Harris as a non-Executive Director on the Company’s Board.
Saturday, December 13, 2014
Abcam Appoints Yvonne Chien as Chief Digital Officer
Abcam’s leadership team strengthened by new appointments.
Saturday, December 13, 2014
Abcam Wins ‘Best Use of Digital Media’ at Life Science Industry Awards
Awards recognise the world’s top performing life science suppliers.
Wednesday, November 19, 2014
Abcam Licenses Multidrug Resistance Protein 4 Inhibitors
Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development.
Tuesday, September 23, 2014
Abcam and Cell Marque Sign Global Strategic Marketing Agreement
Partnership extends Abcam’s reach within in vitro diagnostics market.
Saturday, September 06, 2014
Abcam Establishes New Direct Service for Australia and New Zealand
New service will offer researchers improved delivery times and direct technical support.
Tuesday, August 12, 2014
Abcam Announces Winner of 15 Discoveries Contest
Contest celebrates scientific breakthroughs with $15,000 research grant.
Tuesday, February 04, 2014
Abcam to Open Office in Shanghai
New office will provide dedicated support to Chinese customers.
Tuesday, January 21, 2014
Abcam Named AIM Company of the Year
The AIM awards celebrate outstanding achievement of quoted companies and entrepreneurs who have harnessed AIM to help them fulfil their ambition and growth potential in the last twelve months.
Monday, October 14, 2013
Abcam Appoints Alan Hirzel as Chief Marketing Officer
New role will support future growth strategies at Abcam.
Friday, June 28, 2013
Abcam Signs License Agreement with Pfizer
Company to supply a range of authentic Pfizer compounds to researchers.
Wednesday, June 12, 2013
Abcam Licenses Novel Technology from Columbia University for Neurobiological Research
New products from Abcam Biochemicals will support research into neurodegeneration and drug addiction.
Monday, April 08, 2013
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!